Michael Wessolly
Overview
Explore the profile of Michael Wessolly including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
25
Citations
125
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Olah C, Mairinger F, Wessolly M, Joniau S, Spahn M, Kruithof-de Julio M, et al.
Prostate Cancer Prostatic Dis
. 2024 Nov;
PMID: 39543244
Background: Localized prostate cancer (PCa) is a largely heterogeneous disease regarding its clinical behavior. Current risk stratification relies on clinicopathological parameters and distinguishing between indolent and aggressive cases remains challenging....
2.
Koll F, Weers L, Weigert A, Banek S, Kollermann J, Kluth L, et al.
Mod Pathol
. 2024 Aug;
37(11):100588.
PMID: 39097190
Lymphoepithelioma-like carcinoma of the bladder (LELC-B) is a rare histologic subtype characterized by strong immune cell (IC) infiltrates. A better prognosis and favorable response rates to immune checkpoint inhibitors have...
3.
Henrich L, Greimelmaier K, Wessolly M, Klopp N, Mairinger E, Krause Y, et al.
Genes (Basel)
. 2024 Feb;
15(2).
PMID: 38397199
(1) Colorectal cancer (CRC) is a leading cause of cancer-related deaths globally. Cancer-associated fibroblasts (CAFs) are major components of CRC's tumour microenvironment (TME), but their biological background and interplay with...
4.
Mairinger E, Wessolly M, Buderath P, Borchert S, Henrich L, Mach P, et al.
Front Oncol
. 2023 Nov;
13:1252700.
PMID: 38023247
Background: The underlying mechanism of high T-cell presence as a favorable prognostic factor in high-grade serous ovarian carcinoma (HGSOC) is not yet understood. In addition to immune cells, various cofactors...
5.
Al-Ghazzawi K, Wessolly M, Dalbah S, Ketteler P, Kiefer T, Bechrakis N, et al.
Front Oncol
. 2023 Nov;
13:1144951.
PMID: 37965463
Retinoblastoma (RB) is the most common form of eye cancer experienced in childhood. Its aggressive malignancy is associated with excellent survival rates in high-income countries; however, the prognosis in third-world...
6.
Wyrich M, Ohlig H, Wessolly M, Mairinger E, Steinborn J, Brcic L, et al.
Transl Cancer Res
. 2023 Sep;
12(8):1929-1936.
PMID: 37701096
Background: Malignant pleural mesothelioma (MPM) is an aggressive tumor with a dismal prognosis. Currently, multimodality treatment including chemotherapy with cisplatin or carboplatin in combination with pemetrexed offers the best options....
7.
Borchert S, Mathilakathu A, Nath A, Wessolly M, Mairinger E, Kreidt D, et al.
Int J Mol Sci
. 2023 Aug;
24(15).
PMID: 37569808
The exact mechanism of desmoplastic stromal reaction (DSR) formation is still unclear. The interaction between cancer cells and cancer-associated fibroblasts (CAFs) has an important role in tumor progression, while stromal...
8.
Krekeler C, Wethmar K, Mikesch J, Kerkhoff A, Menck K, Lenz G, et al.
Int J Mol Sci
. 2023 Aug;
24(15).
PMID: 37569431
DNA mismatch repair deficient (dMMR) and microsatellite instable (MSI) metastatic colorectal cancer (mCRC) can be successfully treated with FDA- and EMA-approved immune checkpoint inhibitors (ICI) pembrolizumab and nivolumab (as single...
9.
Stephan-Falkenau S, Streubel A, Mairinger T, Blum T, Kollmeier J, Mairinger F, et al.
Int J Mol Sci
. 2023 Jul;
24(13).
PMID: 37445733
Pulmonary sarcomatoid carcinoma (PSC) has highly aggressive biological behaviour and poor clinical outcomes, raising expectations for new therapeutic strategies. We characterized 179 PSC by immunohistochemistry, next-generation sequencing and in silico...
10.
Hager T, Borchert S, Wessolly M, Mathilakathu A, Mairinger E, Kollmeier J, et al.
Int J Mol Sci
. 2023 Apr;
24(7).
PMID: 37047331
Malignant pleural mesothelioma (MPM) is a mainly asbestos-related tumour associated with a very poor prognosis. Therapeutic approaches include multimodal therapy and chemotherapeutics, with cisplatin being the drug of choice, but...